Discover Archean Chemical Industries And 2 Other Stocks Trading Below Intrinsic Value Estimates On The Indian Exchange
In This Article:
The Indian market increased by 1.0% over the last week and is up 45% over the past 12 months, with earnings forecast to grow by 17% annually. In this thriving environment, identifying stocks trading below their intrinsic value can present significant opportunities for investors looking to capitalize on potential growth.
Top 10 Undervalued Stocks Based On Cash Flows In India
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Everest Kanto Cylinder (NSEI:EKC) | ?183.23 | ?306.00 | 40.1% |
| Apollo Pipes (BSE:531761) | ?592.05 | ?1146.22 | 48.3% |
| Krsnaa Diagnostics (NSEI:KRSNAA) | ?706.70 | ?1165.33 | 39.4% |
| Prataap Snacks (NSEI:DIAMONDYD) | ?838.60 | ?1509.79 | 44.5% |
| Venus Pipes and Tubes (NSEI:VENUSPIPES) | ?2397.60 | ?4385.11 | 45.3% |
| IOL Chemicals and Pharmaceuticals (BSE:524164) | ?436.05 | ?762.32 | 42.8% |
| Updater Services (NSEI:UDS) | ?369.25 | ?619.81 | 40.4% |
| RITES (NSEI:RITES) | ?650.25 | ?1035.60 | 37.2% |
| Artemis Medicare Services (NSEI:ARTEMISMED) | ?274.35 | ?445.15 | 38.4% |
| Manorama Industries (BSE:541974) | ?836.80 | ?1665.51 | 49.8% |
We'll examine a selection from our screener results.
Archean Chemical Industries
Overview: Archean Chemical Industries Limited manufactures and sells specialty marine chemicals in India and internationally, with a market cap of ?87.34 billion.
Operations: Archean Chemical Industries Limited generates revenue primarily from its Marine Chemicals segment, amounting to ?11.99 billion.
Estimated Discount To Fair Value: 10.5%
Archean Chemical Industries appears undervalued based on cash flows, trading at ?707.80, below the estimated fair value of ?791.13. Despite recent penalties totaling over INR 7 million for GST issues and a decline in Q1 earnings to INR 448.57 million from INR 938.56 million last year, its revenue is forecasted to grow at 28.2% annually, outpacing the Indian market's growth rate of 10%. Earnings are also expected to rise significantly by 33.7% per year over the next three years, with a high return on equity forecasted at 24.4%.
Blue Jet Healthcare
Overview: Blue Jet Healthcare Limited manufactures and sells pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for use in pharmaceutical and healthcare products, with a market cap of ?80.64 billion.
Operations: The company's revenue segment primarily consists of the manufacturing and sale of pharmaceutical and healthcare products, generating ?6.95 billion.